Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer. (7th February 2019)

• Record Type: Journal Article
• Authors: Nichols, R. Charles; Morris, Christopher G.; Bryant, Curtis; Hoppe, Bradford S.; Henderson, Randal H.; Mendenhall, William M.; Li, Zuofeng; Costa, Joseph A.; Williams, Christopher R.; Mendenhall, Nancy P.
• Is Part Of: Cancer investigation. Volume 37:Number 2(2019)
• Page Start: 85
• Page End: 89
• Publication Date: 2019-02-07
• Subjects: Serum testosterone -- Bladder and prostate cancer -- Proton therapy -- Radiation oncology; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2019.1565766
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Studies demonstrate a decline of ∼10% in serum testosterone (ST) level after X-ray radiotherapy for prostate cancer. We evaluated changes in ST for patients with low- and intermediate-risk prostate cancer receiving 70-82Gy(RBE) using passive-scatter proton therapy (PT). ST was checked at baseline ( n = 358) and at 60+ months after PT ( n = 166). The median baseline ST was 363.3 ng/dl (range, 82.0–974.0). The median ST 5 years after PT was 391.5 ng/dl (range, 108.0–1061.0). The difference was not statistically significant ( p = 0.9341). Passive-scatter PT was not associated with testosterone suppression at 5 years, suggesting that protons may cause less out-of-field scatter radiation than X-rays.